Immune System News and Research

RSS

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

Nuvo Research second-quarter revenue increases 57% to $4.2 million

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.

31 Jul 2010

WHO expert: Faster MDR-TB test should be made available to vulnerable populations

A new diagnostic tool that shortens the diagnosis of multidrug-resistant tuberculosis (MDR-TB) from eight weeks to two hours should be made available to vulnerable populations according to a WHO expert, Reuters reports.

31 Jul 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

CD74 can serve as prognostic marker for colorectal cancer

CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.

31 Jul 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

Scientist examines relationship between stress of human isolation, immune system

A remote Canadian island is being used to simulate isolated space flight conditions for a NASA-funded medical research study that could produce important information to assist astronauts in potential long duration flights to Mars or an asteroid.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer. The Japanese team is reporting in a Journal of Biological Chemistry "Paper of the Week" that they are optimistic that inhibiting a protein found on the surface of blood cells known as platelets may combat both irregular blood clotting and the spread of certain cancers throughout the body.

30 Jul 2010

White button mushrooms can keep the immune system healthy: Study

Mushrooms are among the many foods thought to play an important role in keeping the immune system healthy. Now, Agricultural Research Service funded scientists have conducted an animal-model and cell-culture study showing that white button mushrooms enhanced the activity of critical cells in the body's immune system.

30 Jul 2010

New paradigm in TB research may lead to improved vaccination, treatment

Often causing no symptoms in carriers of the disease, worldwide tuberculosis (TB) infects eight to ten million people every year, kills two million, and it is highly contagious as it is spread through coughing and sneezing. "It's a global health disaster waiting to happen, even here in Canada, but this new paradigm in TB research may offer an immediate opportunity to improve vaccination and treatment initiatives," explains Dr. Maziar Divangahi of McGill University and of the Research Institute of the McGill University Health Centre.

30 Jul 2010

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.

29 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Researchers find how angiotensin influences immune system

Researchers in Heidelberg and Stanford have discovered a new signalling pathway of brain cells that explains how widely used antihypertensive drugs could keep inflammation in multiple sclerosis in check. The peptide angiotensin not only raises blood pressure but also activates the immunological messenger substance TGF beta on a previously unknown communication pathway in the brain.

29 Jul 2010

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

Advanced Cell Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).

29 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

Advanced Protein Systems is now APS BioGroup

APS BioGroup, formerly Advanced Protein Systems, the world's largest producer of colostrum products, announces its new company name and expanded focus to include advancements in private label contract manufacturing for health supplements and the introduction of Immulox®, an immune support product and supplement ingredient derived from colostrum.

29 Jul 2010

Immune System News and Research

Cell-of-origin for prostate cancer identified

Nuvo Research second-quarter revenue increases 57% to $4.2 million

WHO expert: Faster MDR-TB test should be made available to vulnerable populations

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

CD74 can serve as prognostic marker for colorectal cancer

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Scientist examines relationship between stress of human isolation, immune system

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

New findings on snake venom toxin hold promise for developing heart disease, cancer therapies

White button mushrooms can keep the immune system healthy: Study

New paradigm in TB research may lead to improved vaccination, treatment

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Researchers find how angiotensin influences immune system

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advanced Protein Systems is now APS BioGroup

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News